Radioimmunotherapy with 131 I-rituximab for patients with relapsed or refractory follicular or mantle cell lymphoma.

Yoon Jung JangSang Moo LimInki LeeByung Hyun ByunIlhan LimByung Il KimChang Woon ChoiSeung-Sook LeeCheolwon SuhDok Hyun YoonInho KimSeung-Hyun NamMark Hong LeeJong Ho WonJee Hyun KongSeong Hyun JeongSuk Joong OhKeon Woo ParkJae Joon HanMoo-Kon SongSung Hyun YangIm Il NaHyo-Rak LeeDong-Yeop ShinHye Jin Kang

Published in: Asia-Pacific journal of clinical oncology (2023)

I-rituximab has an effective and favorable safety profile in patients with relapsed or refractory follicular lymphoma and mantle cell lymphoma. This suggests that RIT may also be considered a treatment option for patients with relapsed or refractory follicular lymphoma and mantle cell lymphoma.

Keyphrases

diffuse large b cell lymphoma
hodgkin lymphoma
acute lymphoblastic leukemia
acute myeloid leukemia
multiple myeloma
combination therapy
smoking cessation